

November 27, 2025

To,

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited

Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Dear Sir/ Madam,

Pursuant to Regulation 30 (read with Part A of Schedule III) of the SEBI Listing Regulations, we wish to inform you that the Board of Directors *vide* circular resolution passed today i.e. November 27, 2025, considered and approved the following:

- a) basis the name reservation letter received from CRC dated November 17, 2025, change in name of the Company from "Sequent Scientific Limited" to "**Viyash Scientific Limited**", and consequential alteration to the Memorandum of Association and Articles of Association of the Company to give effect to the change in name of the Company and
- b) Alteration in main object clause of the Memorandum of Association of the Company pursuant to the Scheme (*as defined below*), in order to incorporate and align the objects of the merging entities with those of the Company.

The above approvals are further subject to:

- a) effectiveness of the composite scheme of amalgamation among the Company, Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Geninn Life Sciences Private Limited, Sequent Research Limited and their respective shareholders and creditors ("**Scheme**") and
- b) approval of the shareholders of the Company and other regulatory authorities, as may be applicable.

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

The brief details of the amendment to the Memorandum of Association and Articles of Association of the Company pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, is enclosed herewith as **Annexure – A.**

Kindly take the same on record.

Yours faithfully,
For Sequent Scientific Limited

Yoshita Vora
Company Secretary & Compliance Officer
Encl: As above

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

Annexure A

Amendments to memorandum and articles of association of the Company, in brief.

Sl No.	Particulars	Details
1.	Memorandum of Association ("MOA")	a) Name Clause: Subject to effectiveness of the Scheme, approval of the shareholders of the Company, and upon issuance of the Certificate of Incorporation pursuant to change in name by the Registrar of Companies, "Sequent Scientific Limited" be substituted with "Viyash Scientific Limited" wherever it appears in the MOA including Clause I of the MOA. b) Object Clause: Subject to effectiveness of the Scheme and approval of the shareholders of the Company, the main objects clause of the MOA of the Company in Clause III(A)1. of the MOA be substituted in the following manner: "III(A)1.(i) To carry on the business of manufacturers, processors, producers, makers, importers, exporters, buyers, sellers, suppliers, stockists, agents, merchants, distributors and concessionaries of: (a) bulk drugs, APIs (Active pharmaceutical ingredients), drug intermediates, derivatives, excipients, pharmaceutical raw materials, parasitocides, pesticides, fungicides, weedocides, herbal and ayurvedic ingredients, natural extracts, pigments, pharmaceutical formulations and finished dosage forms for human and veterinary use (including parenterals, injections, oral solids, semi-solids, oral liquids, sprays, topical preparations, and other regulated and non-regulated dosage forms) and to deal in chemicals, solvents and other materials used in the development, manufacture or testing of pharmaceutical and life-science products for human and veterinary use. (b) Cosmetic and medicinal preparations required or used for beauty aid, personal hygiene or in allopathic, ayurvedic, homeopath, unani or nature cure methods or system of treatments. (c) Bandages, cotton, gauzes, crutches, stretchers and all kinds of anatomical, orthopaedic and surgical appliances and stores including prophylactics. (ii) To engage in pharmaceuticals, life sciences, contract development and manufacturing(CDMO) activities, including research and development, process development, testing, investigation, analysis, quality assurance quality control,

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | CIN: L99999TS1985PLC196357

Website: <http://www.sequent.in> | Email Id: investorrelations@sequent.in

		microbiological, toxicological and bioavailability related studies and to render technical regulatory and compliance consultancy and training in all the above fields and to establish, maintain and operate testing laboratories for own use and third parties in India or abroad and obtain all necessary patents, licenses and approvals. (iii) To manufacture on loan license or own license basis and to deal in all types of oil, oil products, oil seeds, fatty acids and their esters, amines, ion-exchange resins, adhesive resins, nitriles, amides, polyamides, soaps, toiletry preparations, emulsifiers, floatation agents, animal feeds and fertilizers. (iv) To establish and carry on the business, assemble, convert, buy, produce, procure, sell, distribute, trade, act as agents, suppliers, transporters, brokers, wholesalers, retailers, stockist, godown keeper, C&F agents, del credere agent, job worker, refiners, analytical service providers. (v) To deal in vaccines, sera, biologics, immunological and biotechnological products, fermentation products, hormones, steroids, antibiotics, anti-microbial and antidiabetic products, herbal products, nutraceuticals, chemical substances used in pharmaceutical manufacturing and all related by-products, residues, compounds and preparations, as well as medical, surgical and diagnostic equipment, devices and apparatus used in healthcare and therapeutic applications. (vi) To carry out all the above activities subject to obtaining requisite licences, permissions, consents, registrations and approvals from the competent authorities, and in compliance with applicable laws, rules, regulations, standards and guidelines in India or abroad.
2.	Articles of Association ("AOA")	Subject to effectiveness of the Scheme, approval of the shareholders of the Company, and upon issuance of the Certificate of Incorporation pursuant to change in name by the Registrar of Companies, "Sequent Scientific Limited" be substituted by "Viyash Scientific Limited" wherever it appears in the AOA.

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in